Loading...
The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy
Background: The programmed death 1 (PD1)/programmed death ligand 1 (PDL1) targeted therapies have gained positive outcomes in several tumors, but the evidence of the expression and prognosis value of PD1/PDL1 in high risk prostate cancer was rare. Methods: Immunohistochemical analysis of PDL1/PD1 ex...
Na minha lista:
| Udgivet i: | J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ivyspring International Publisher
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6603373/ https://ncbi.nlm.nih.gov/pubmed/31289580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.30384 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|